Literature DB >> 22750327

Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.

Melanie B Watson1, Franziska Richter, Soo Kyung Lee, Lauryn Gabby, Jennifer Wu, Eliezer Masliah, Rita B Effros, Marie-Françoise Chesselet.   

Abstract

Parkinson's disease (PD) is characterized by widespread alpha-synuclein pathology and neuronal loss, primarily of the nigrostriatal dopaminergic neurons. Inflammation has been implicated in PD, and alpha-synuclein can initiate microglial activation; however, the kinetics and distribution of inflammatory responses to alpha-synuclein overexpression in vivo are not well understood. We have examined the regional and temporal pattern of microglial activation and pro-inflammatory cytokine production in mice over-expressing wild-type human alpha-synuclein driven by the Thy1-promoter (Thy1-aSyn mice). An increased number of activated microglia, and increased levels of TNF-α mRNA and protein were first detected in the striatum (1 month of age) and later in the substantia nigra (5-6 months), but not the cerebral cortex or cerebellum; in contrast, IL-1β and TGF-β remained unchanged in the striatum and substantia nigra at all ages examined. Microglial activation persisted up to 14 months of age in these regions and only minimal increases were observed in other regions at this later age. Increased concentrations of serum TNF-α were observed at 5-6 months, but not at 1 month of age. The expression of toll-like receptors (TLRs) 1, TLR 4 and TLR 8, which are possible mediators of microglial activation, was increased at 5-6 months in the substantia nigra but not in the cerebral cortex, and TLR 2 was increased in the substantia nigra at 14 months of age. With the exception of a slight increase in the striatum of 14 month old Thy1-aSyn mice, MHCII staining was not detected in the regions and ages examined. Similarly, peripheral CD4 and CD8-postive T cells were increased in the blood but only at 22 months of age, suggesting later involvement of the adaptive immune response. These data indicate that, despite the presence of high levels of alpha-synuclein in other brain regions, alpha-synuclein overexpression caused a selective early inflammatory response in regions containing the axon terminals and cell bodies of the nigrostriatal pathway. Our results suggest that specific factors, possibly involving a regionally and temporally selective increase in TLRs, mediate alpha-synuclein-induced inflammatory responses in the SN, and may play a role in the selective vulnerability of nigrostriatal dopaminergic neurons in PD.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750327      PMCID: PMC3443323          DOI: 10.1016/j.expneurol.2012.06.025

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  65 in total

Review 1.  Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism.

Authors:  Sheila M Fleming; Marie-Françoise Chesselet
Journal:  Behav Pharmacol       Date:  2006-09       Impact factor: 2.293

2.  Alterations of T-lymphocyte populations in Parkinson disease.

Authors:  Yasuhiko Baba; Ataru Kuroiwa; Ryan J Uitti; Zbigniew K Wszolek; Tatsuo Yamada
Journal:  Parkinsonism Relat Disord       Date:  2005-09-09       Impact factor: 4.891

Review 3.  Role of cytokines in inflammatory process in Parkinson's disease.

Authors:  M Sawada; K Imamura; T Nagatsu
Journal:  J Neural Transm Suppl       Date:  2006

4.  Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication.

Authors:  J Fuchs; C Nilsson; J Kachergus; M Munz; E-M Larsson; B Schüle; J W Langston; F A Middleton; O A Ross; M Hulihan; T Gasser; M J Farrer
Journal:  Neurology       Date:  2007-01-24       Impact factor: 9.910

5.  Peripheral cytokines profile in Parkinson's disease.

Authors:  M Reale; C Iarlori; A Thomas; D Gambi; B Perfetti; M Di Nicola; M Onofrj
Journal:  Brain Behav Immun       Date:  2008-07-17       Impact factor: 7.217

6.  Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway.

Authors:  Nanping Wu; Prasad R Joshi; Carlos Cepeda; Eliezer Masliah; Michael S Levine
Journal:  J Neurosci Res       Date:  2010-06       Impact factor: 4.164

7.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

Review 8.  Modelling of Parkinson's disease in mice.

Authors:  Marie-Françoise Chesselet; Franziska Richter
Journal:  Lancet Neurol       Date:  2011-12       Impact factor: 44.182

9.  Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.

Authors:  Edward Rockenstein; Margaret Mallory; Makoto Hashimoto; David Song; Clifford W Shults; Ingrid Lang; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2002-06-01       Impact factor: 4.164

10.  Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.

Authors:  Shaji Theodore; Shuwen Cao; Pamela J McLean; David G Standaert
Journal:  J Neuropathol Exp Neurol       Date:  2008-12       Impact factor: 3.685

View more
  83 in total

1.  Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Authors:  Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

2.  An Anatomically Resolved Mouse Brain Proteome Reveals Parkinson Disease-relevant Pathways.

Authors:  Sung Yun Jung; Jong Min Choi; Maxime W C Rousseaux; Anna Malovannaya; Jean J Kim; Joachim Kutzera; Yi Wang; Yin Huang; Weimin Zhu; Suman Maity; Huda Yahya Zoghbi; Jun Qin
Journal:  Mol Cell Proteomics       Date:  2017-02-02       Impact factor: 5.911

3.  Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson's Disease: A Pilot Study.

Authors:  Amit Khairnar; Peter Latta; Eva Drazanova; Jana Ruda-Kucerova; Nikoletta Szabó; Anas Arab; Birgit Hutter-Paier; Daniel Havas; Manfred Windisch; Alexandra Sulcova; Zenon Starcuk; Irena Rektorova
Journal:  Neurotox Res       Date:  2015-07-08       Impact factor: 3.911

4.  X-linked Dystonia-Parkinsonism patient cells exhibit altered signaling via nuclear factor-kappa B.

Authors:  Christine A Vaine; David Shin; Christina Liu; William T Hendriks; Jyotsna Dhakal; Kyle Shin; Nutan Sharma; D Cristopher Bragg
Journal:  Neurobiol Dis       Date:  2016-12-22       Impact factor: 5.996

5.  A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.

Authors:  Franziska Richter; Sudhakar R Subramaniam; Iddo Magen; Patrick Lee; Jane Hayes; Aida Attar; Chunni Zhu; Nicholas R Franich; Nicholas Bove; Krystal De La Rosa; Jacky Kwong; Frank-Gerrit Klärner; Thomas Schrader; Marie-Françoise Chesselet; Gal Bitan
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

6.  Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

Authors:  Omar El-Agnaf; Cassia Overk; Edward Rockenstein; Michael Mante; Jazmin Florio; Anthony Adame; Nishant Vaikath; Nour Majbour; Seung-Jae Lee; Changyoun Kim; Eliezer Masliah; Robert A Rissman
Journal:  Neurobiol Dis       Date:  2017-05-02       Impact factor: 5.996

7.  Synthesis and biological evaluation of substituted N-[3-(1H-pyrrol-1-yl)methyl]-1,2,5,6-tetrahydropyridin-1-yl]benzamide/benzene sulfonamides as anti-inflammatory agents.

Authors:  Madhavi Gangapuram; Elizabeth Mazzio; Suresh Eyunni; Karam F A Soliman; Kinfe K Redda
Journal:  Arch Pharm (Weinheim)       Date:  2014-03-02       Impact factor: 3.751

Review 8.  Parkinson's disease and enhanced inflammatory response.

Authors:  Iva Stojkovska; Brandon M Wagner; Brad E Morrison
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

10.  Screening of Toll-like receptors expression in multiple system atrophy brains.

Authors:  Tomasz Brudek; Kristian Winge; Tina Klitmøller Agander; Bente Pakkenberg
Journal:  Neurochem Res       Date:  2013-03-23       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.